Stephanie Fox-Rawlings, April 13 2017: At an FDA meeting, NCHR explained that developing new antibiotics for rare, low-risk bacteria could do more harm than good by exposing patients to unnecessary side effects, increasing the chances of drug-resistant infections, and diverting resources away from treatments that are truly needed.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Testimony at FDA on Opioid, Opana ER
March 14, 2017. Compared with other opioids, reformulated Opana ER, along with its generic counterpart, had the highest injection abuse rates following reformulation.
Read More »NCHR Testimony at FDA Meeting about Abuse-Deterrent Opioid, Roxybond
April 5, 2017. Dr. Megan Polanin testifies at the FDA, stating that there is still abuse potential for the intranasal and intravenous use of RoxyBond in the midst of the nation’s opoiod epidemic.
Read More »NCHR Testimony at FDA on Hangover Treatments
April 4, 2017. Like many public health experts and advocates, we are very concerned about treatments that are marketed and promoted for hangovers that contain either acetaminophen or aspirin.
Read More »NCHR Comment on the USPSTF’s Draft Recommendations for Vision Screening in Young Children
March 27, 2017. NCHR supports USPSTF’s draft recommendation for vision screening in young children as well as their broader efforts to improve the health of all Americans by making evidence-based recommendations about clinical preventive services. As more information becomes available, we encourage the provision of additional recommendations about procedures that improve the benefits of vision tests for children and their families.
Read More »